The latest rejection looks set to mark the end of J&J's drive to resolve the litigation through the bankruptcy courts, as the ...

Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...

Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...

Reducing levels of LDL-cholesterol can reduce the risk of dementia by 26%, according to a new study, which also suggests ...

With the world braced for an announcement of sweeping tariffs later today by President Donald Trump, analysts at ING have ...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an ...

Prosecutors in the US are seeking the death penalty for Luigi Mangione, the man detained in connection with the assassination ...

Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...

The Labour manifesto pledged to “maximise our potential to lead the world in clinical trials”. With our regulatory advantage ...

Novo Nordisk's Ozempic has been shown to improve waking distance and quality of life in people with type 2 diabetes (T2D) and ...

EVERSANA – pharmaphorum's parent company – said it has met the standard to join Veeva's partner programme and will now be ...

Italy's Chiesi Group has revealed plans to spend €430 million ($464 million) on a new therapeutics manufacturing facility at ...